• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Legal News

Tandem agrees to pay $36M to settle Roche patent litigation

May 29, 2025 By Sean Whooley

Tandem Diabetes Care Roche

Tandem Diabetes Care (Nasdaq:TNDM) recently filed an SEC Form 8-K announcing its entry into a patent litigation settlement with Roche. The two companies entered into a settlement, mutual release and cross-license agreement. It resolves all actual or potential patent disputes as of May 21. According to the SEC filing, the settlement relates to Tandem’s t:slim […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Legal News, Regulatory/Compliance, Technology Tagged With: Roche, Roche Diabetes Care, Tandem Diabetes Care

BD files patent infringement lawsuit against Baxter over infusion pump tech

May 13, 2025 By Sean Whooley

Baxter Novum IQ Infusion (BD alleges patent infringement against the system)

BD (NYSE:BDX) filed a lawsuit in a U.S. District Court alleging patent infringement by Baxter (NYSE:BAX) related to infusion pump technology. The company filed its complaint in the U.S. District Court for the District of Delaware on May 12, 2025. BD’s complaint singles out six specific patents: the “180,” “058,” “880,” “868,” “414,” and “703” […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Legal News, Technology Tagged With: Baxter, BD

Insulet earns insulin patch pump patent victory against EOFlow with permanent injunction

April 29, 2025 By Sean Whooley

Medtronic EOFlow EOPatch Insulet Omnipod 5

A judge has issued a permanent injunction, signaling an Insulet (Nasdaq:PODD) victory in a trade secret case against EOFlow. The permanent injunction highlights the successful defense of Insulet’s intellectual property. Subsequently, the damages award was reduced from $452 million to $60 million at Insulet’s election. The company wanted the permanent injunction instead of the higher […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Legal News, Regulatory/Compliance, Technology Tagged With: eoflow, Insulet

How ICU Medical plans to mitigate tariff impact

April 8, 2025 By Sean Whooley

This is the logo of ICU Medical.

Needham analysts report that ICU Medical (Nasdaq: ICUI) has a plan in place to handle its exposure to the tariffs imposed by the Trump Administration. Medtech stocks already took a hit last month as in response to Trump’s tariff policies. Trump’s rollout of new taxes on imports from nearly all countries last week triggered the latest market dip. […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Legal News, Technology, Wall Street Beat Tagged With: ICU Medical

Sinocare prevails in CGM trademark spat with Abbott

February 12, 2025 By Sean Whooley

Sinocare iCan i3 CGM (1) (1)

Sinocare announced recently that it successfully defended itself in court against trademark infringement claims brought by Abbott (NYSE:ABT). The China-based continuous glucose monitor (CGM) maker defended itself in the High Court of Justice (Chancery Division) of England and Wales against claims regarding trademark infringement and passing off. Abbott claimed that Sinocare’s iCan i3 CGM system […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Legal News, Patient Monitoring, Regulatory/Compliance, Technology Tagged With: abbott, sinocare

Abbott, Dexcom settle global CGM patent litigation

December 23, 2024 By Sean Whooley

Dexcom G7 Abbott FreeStyle Libre 2 CGM

Abbott (NYSE:ABT) announced today that it reached an agreement with Dexcom (Nasdaq:DXCM) to settle all outstanding patent disputes between companies. The patent litigation relates to the companies’ continuous glucose monitor (CGM) technologies. Abbott and Dexcom are two leaders in the CGM space. They offer market-leading platforms, with Abbott’s FreeStyle Libre 3 and Dexcom’s G7 representing […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Legal News, Patient Monitoring, Regulatory/Compliance Tagged With: abbott, Dexcom

BD to pay SEC $175M to settle Alaris investigation

December 17, 2024 By Sean Whooley

BD Alaris Infusion System updated FDA clearance

BD (NYSE:BDX) announced that it reached an agreement with the SEC to resolve an investigation related to its Alaris system. The investigation relates to prior public disclosures and SEC reporting regarding Alaris, an infusion pump system. BD neither admits nor denies the findings of an SEC order related to those matters occurring more than four years […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Legal News, Regulatory/Compliance Tagged With: Alaris, BD

European court rules in favor of Abbott in Dexcom CGM patent spat

December 12, 2024 By Sean Whooley

Dexcom G7 Abbott FreeStyle Libre 2 CGM

The Unified Patent Court in Paris sided with Abbott (NYSE:ABT) following a CGM patent infringement claim from Dexcom (Nasdaq:DXCM). Abbott and Dexcom are two leaders in the continuous glucose monitoring (CGM) space. They offer market-leading platforms, with Abbott’s FreeStyle Libre 3 and Dexcom’s G7 representing their latest-generation technologies. Dexcom requested that the court find infringement […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Legal News, Patient Monitoring, Regulatory/Compliance, Technology Tagged With: abbott, Dexcom

Insulet prevails in IP battle with patch pump maker EOFlow

December 5, 2024 By Sean Whooley

Medtronic EOFlow EOPatch Insulet Omnipod 5

Insulet (Nasdaq:PODD) announced that it successfully defended its intellectual property against EOFlow in U.S. federal court. Both companies develop automated insulin delivery systems utilizing patch pump technology. Insulet offers the market-leading Omnipod platform, while Korea-based EOFlow develops the EOPatch — similarly, a tubeless, wearable and fully disposable insulin delivery device. EOFlow was at one point […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Legal News, Technology Tagged With: eoflow, Insulet

Class action suit targets Abbott FreeStyle Libre amid claims of data sharing

September 18, 2024 By Sean Whooley

Abbott FreeStyle Libre 2

Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre platform. ClassAction.org first reported on the claims. The lawsuit alleges that tracking tools on Abbott’s FreeStyle Libre website expose private consumer information without their knowledge or consent. Its FreeStyle.Abbott website provides educational tools for the continuous glucose […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Legal News, Patient Monitoring, Technology Tagged With: abbott

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 17
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS